Function of tumor suppressors in resistance to antiandrogen therapy and luminal epithelial plasticity of aggressive variant neuroendocrine prostate cancers

Research output: Contribution to journalShort surveypeer-review

5 Scopus citations

Abstract

Combined loss of tumor suppressors (TSPs), PTEN, TP53, and RB1, is highly associated with small cell carcinoma of prostate phenotype. Recent genomic studies of human tumors as well as analyses in mouse genetic models have revealed a unique role for these TSPs in dictating epithelial lineage plasticity-a phenomenon that plays a critical role in the development of aggressive variant prostate cancer (PCa) and associated androgen therapy resistance. Here, we summarize recently published key observations on this topic and hypothesize a possible mechanism by which concurrent loss of TSPs could potentially regulate the PCa disease phenotype.

Original languageEnglish (US)
Article number69
JournalFrontiers in Oncology
Volume8
Issue numberMAR
DOIs
StatePublished - Mar 15 2018

Keywords

  • Epithelial-to-mesenchymal transition
  • Lineage plasticity
  • Neuroendocrine prostate cancer
  • Therapy resistance
  • Tumor suppressors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Function of tumor suppressors in resistance to antiandrogen therapy and luminal epithelial plasticity of aggressive variant neuroendocrine prostate cancers'. Together they form a unique fingerprint.

Cite this